Nventa Biopharmaceuticals Corporation is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). 

The Company's lead initiative is the development of HspE7, a therapeutic vaccine for the possible treatment of patients with cervical dysplasia, recurrent respiratory papillomatosis and genital warts.  Headquartered in San Diego, CA, Nventa Common Stock trades on the Toronto Stock Exchange (TSX) under the symbol: NVN.

Corporate Fact Sheet (PDF)

Insight to Impact™, the Company's tagline introduced in June of 2006, communicates its mission of applying scientific insight to discover novel drugs that have a direct impact on patients suffering from difficult-to-treat diseases with few treatment options.

August 12 2008:
Nventa Biopharmaceuticals Corporation Announces Second Quarter 2008 Financial Results And Recent Corporate Highlights

July 29 2008:
Nventa Wins European Patent Challenge Covering Lead Product Candidate HSPE7 And Other HPV Therapeutics

July 28 2008:
Nventa Announces Final Data From HSPE7 Phase 1 Cervical Dysplasia Trial

June 18 2008:
Nventa Develops Proprietary Vaccine Adjuvant